Navigation Links
A New Drug That Could Revolutionize Management Of Heart Disease

In a study published in the Journal of Clinical Investigation and the September issue of Nature Reviews/Drug Discovery//, researchers at Monash University have reported that a new drug helps in reducing the risk of high blood pressure and heart attacks by improving the blood flow in diseased arteries. The new drug developed by Bayer HealthCare was found to reactivate a key enzyme, damaged by free radicals, which helps in dilatation of the arteries.

The finding is a significant development for the Monash team that, in conjunction with Bayer Health Care, hopes to use the drug as part of a revolution in the management of heart disease.

Dr. Harald Schmidt, Director of the Centre for Vascular Health and his colleagues at Monash University, Dr. Peter Schmidt and Barbara Kemp-Harper, say the next step will be to translate the research so it benefits patients. Clinical trials of the drug have already started for the treatment of acute heart failure.

Dr. Schmidt's team and colleagues in Germany and the US have previously shown that oxidative stress - the appearance of free radicals in the walls of arteries - is a key mechanism underlying cardiovascular disease.

"Free radicals contribute to the formation of arterial blockages. What's more, as the number of free radicals increases, they also interfere with the ability of the cells lining arteries to control the contraction and dilation of the arteries," Dr. Schmidt says. "The arteries stiffen and get blocked."

When a blockage occurs, the cells lining the arteries produce nitric oxide to signal to the arterial muscles that they need to dilate the artery and allow more blood through. But free radicals destroy a key enzyme that allows the arterial cells to respond in this way, so the signal doesn't get through.

However, the new drug – developed by Bayer HealthCare – reactivates the damaged enzyme.

"Our results show that the drug directly binds to and repairs the damaged enzyme. And as the number of free radicals increases, the drug starts working harder," says Dr. Schmidt. The results have been published in the Journal of Clinical Investigation and the September issue of Nature Reviews/Drug Discovery.

Dr. Schmidt, together with clinical and basic science colleagues, is creating a new research centre at Monash with the aim of challenging orthodox thinking on heart disease and stroke.

"Vascular diseases are the number one cause of death worldwide. Yet we don't know enough about the causes to reliably identify and treat cases, let alone prevent these diseases," he says. "In up to 95 per cent of cases, the root causes of vascular diseases are still unknown. So clinicians have to rely on 'lifestyle' indicators and 'risk factors' such as high blood pressure and high cholesterol.

"However, not all people with high blood pressure or high cholesterol experience heart attack or stroke At the same time, many people without any apparent risk factors have unexpected heart attacks and strokes. We need a revolution in vascular diagnosis, treatment and prevention. This discovery is an important step along the way."

Source-Eurekalert
SA
'"/>




Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Nasal Spray Could Take Drugs Direct to Brain.
3. Nasal Spray Could Take Drugs Directly to Brain
4. Oxygen Usage During Exercise Could Indicate Heart Problems
5. Ultrasound Screening Could Improve The Outcome Of Critically ill Patients
6. Anger Could Be Linked To Weight Gain
7. A Seizure Late In Life Could be A Stroke Warning
8. New Findings Could Reduce The Extent Of Spinal Cord Injuries
9. Could There Be A Link Between Famine and Breast Cancer ?
10. Bone Marrow Cells Could Yield A New Lease of Life
11. New Hair in 15 Days Could Now Be A Possibility Say Researchers
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... ... September 19, 2017 , ... The ... Canyon Ranch to its recently formed Corporate Roundtable, a group of individuals ... and a sustainable world. , Canyon Ranch is a unique collection of lifestyle-based ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... present, Mirixa Corporation recently unveiled the MirixaPro 6.0 platform. As the industry’s ... medication management services are delivered. Based on industry research and market feedback, ...
(Date:9/19/2017)... ... September 19, 2017 , ... Driving Dynamics Inc., announced today it ... Training Industry Inc. as part of its mission to continually monitor the training marketplace ... first annual 2017 Top 20 Health and Safety Training Companies list was based on ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... by a neurosurgeon, has received a big bump in sales after recently ... is currently available on the Wal-Mart Stores-owned Jet.com, StackedNutrtion.com, RonnieColemanNutrition.com, RevNutrition.com and ...
(Date:9/19/2017)... New York (PRWEB) , ... September 19, 2017 , ... ... dentist, Dr. Andrew Sami, was recently named one of the best dentists in America ... lifestyle magazine for dental professionals nationwide. Every fall, the magazine features the best 40 ...
Breaking Medicine News(10 mins):
(Date:9/6/2017)... ANTONIO , Sept. 6, 2017  Robert G. ... a Pinnacle Professional Member in recognition of his contributions ... Szewc serves as a Nephrologist at the practice of ... emergency medicine, kidney care and hypertension solutions. He has ... 20 years of career experience, as well as expertise ...
(Date:9/6/2017)... ORANGEBURG, N.Y. , Sept. 6, 2017   PDI ... today announced it will host an educational session focused ... line-associated bloodstream infection (CLABSI) prevention at the 2017 Annual ... meeting, which will take place at the ... Arizona from Sept. 16-19, will also feature ...
(Date:9/6/2017)... , Sept. 6, 2017 Eli Lilly ... it will present new data for galcanezumab and lasmiditan, ... of the International Headache Society (IHC) taking place Sept. ... Lilly will highlight new, long-term data from an ... doses of galcanezumab (120 mg and 240 mg) for ...
Breaking Medicine Technology: